Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China.
Department of Pathology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, 200031, People's Republic of China.
Eur Arch Otorhinolaryngol. 2019 Nov;276(11):3113-3122. doi: 10.1007/s00405-019-05601-7. Epub 2019 Aug 26.
Definitive radiotherapy (RT) is recommended by NCCN guidelines for T4b tumors of sinonasal squamous cell carcinomas (SNSCC). However, no multi-institutional clinical studies have proved its advantage over surgery-based modalities. The aim of this study was to assess the survival of T4bN0M0 SNSCC patients who received surgery plus postoperative radiation (S + PORT) compared with those who received RT.
This study extracted 220 patients from the SEER database from 2004 to 2015. Propensity score matching (PSM) was used to eliminate the baseline variations.
In SEER database, 43.6% of patients received S + PORT, and subsequently followed by RT (36.4%). Five-year overall survival (OS) and cancer-specific survival rates (CSS) in S + PORT were 42.5% and 46.9%, respectively, significantly better than for RT (21.7% and 26.7%). Multivariate analysis showed that therapy of RT had higher cancer-specific mortality risk than S + PORT [hazard ratio (HR) 1.578, p = 0.032]. After PSM, 57 pairs of patients were selected. There was still a significant difference noted with regard to 5-year OS or 5-year CSS between patients receiving S + PORT and RT (43% vs 22.5%, p = 0.012; 45.8% vs 27.7%, p = 0.025). The univariate and multivariate analyses of factors predictive of CSS showed that therapy of RT (HR 1.877, p = 0.018) and primary subsite of maxillary sinus (HR 2.629, p = 0.001) were significantly correlated with adverse outcomes.
Combination of surgery and postoperative radiotherapy may contribute to prolonged survival in T4bN0M0 SNSCC. Invasion of the sites of T4b tumors is not an absolute contraindication for surgery.
NCCN 指南建议对鼻窦鳞状细胞癌(SNSCC)的 T4b 肿瘤采用确定性放疗(RT)。然而,尚无多机构临床研究证明其优于基于手术的治疗方式。本研究旨在评估接受手术加术后放疗(S+PORT)的 T4bN0M0 SNSCC 患者的生存情况,并与接受 RT 的患者进行比较。
本研究从 2004 年至 2015 年从 SEER 数据库中提取了 220 例患者。采用倾向评分匹配(PSM)消除基线差异。
在 SEER 数据库中,43.6%的患者接受了 S+PORT,随后接受了 RT(36.4%)。S+PORT 的 5 年总生存率(OS)和癌症特异性生存率(CSS)分别为 42.5%和 46.9%,显著优于 RT(21.7%和 26.7%)。多因素分析显示,RT 治疗的癌症特异性死亡率高于 S+PORT[风险比(HR)1.578,p=0.032]。PSM 后,选择了 57 对患者。接受 S+PORT 和 RT 的患者在 5 年 OS 或 5 年 CSS 方面仍存在显著差异(43%比 22.5%,p=0.012;45.8%比 27.7%,p=0.025)。CSS 的单因素和多因素分析表明,RT 治疗(HR 1.877,p=0.018)和上颌窦原发部位(HR 2.629,p=0.001)是与不良结局显著相关的因素。
手术联合术后放疗可能有助于延长 T4bN0M0 SNSCC 患者的生存时间。T4b 肿瘤部位的侵犯并非手术的绝对禁忌证。